COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis

JW Senefeld, M Franchini, C Mengoli… - JAMA Network …, 2023 - jamanetwork.com
Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019

EM Bloch, D Focosi, S Shoham… - Clinical Infectious …, 2023 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …

Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses.

D Focosi, JW Senefeld, MJ Joyner… - British journal of …, 2023 - search.ebscohost.com
Patients transfused with at least two CCP units (patients nos 1-4 and patients nos 7 and 8)
cleared the virus faster (median 21 days vs 32 days) than patients receiving only one CCP …

Effectiveness of COVID-19 convalescent plasma (CCP) during the pandemic era: a literature review

UR Kandula, TS Tuji, DB Gudeta… - Journal of Blood …, 2023 - Taylor & Francis
Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World …

[HTML][HTML] Efficacy of convalescent plasma to treat long-standing COVID-19 in patients with B-cell depletion

L Tomisti, F Angelotti, M Lenzi, F Amadori, G Sarteschi… - Life, 2023 - mdpi.com
The use of antivirals, corticosteroids, and IL-6 inhibitors has been recommended by the
WHO to treat COVID-19. CP has also been considered for severe and critical cases. Clinical …

[PDF][PDF] VIEWPOINTS ARTICLE

EM Bloch, D Focosi, S Shoham, J Senefeld, A AR - 2023 - scholar.archive.org
COVID-19 convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in
immune compromised (IC) patients. IC patients have a higher risk of persistent infection …

[PDF][PDF] COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review. 2

JW Senefeld, M Franchini, C Mengoli, M Cruciani… - scholar.archive.org
Interventions–Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration 111
http://www. cochranehandbook. org.]. The Cochrane'Risk of bias' tool for RCTs addresses …